Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial

Carla Guerriero, John Cairns, Pablo Perel, Haleema Shakur, Ian Roberts, CRASH 2 trial collaborators, Carla Guerriero, John Cairns, Pablo Perel, Haleema Shakur, Ian Roberts, CRASH 2 trial collaborators

Abstract

Objective: To assess the cost effectiveness of giving tranexamic acid (TXA) to bleeding trauma patients in low, middle and high income settings.

Methods: The CRASH-2 trial showed that TXA administration reduces the risk of death in bleeding trauma patients with a small but statistically significant increase in non-intensive care stay. A Markov model was used to assess the cost effectiveness of TXA in Tanzania, India and the United Kingdom (UK). The health outcome was the number of life years gained (LYs). Two costs were considered: the cost of administering TXA and the cost of additional days in hospital. Cost data were obtained from hospitals, World Health Organization (WHO) database and UK reference costs. Cost-effectiveness was measured in international dollars ($) per LY. Both deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results to model assumptions.

Findings: Administering TXA to bleeding trauma patients within three hours of injury saved an estimated 372, 315 and 755 LYs per 1,000 trauma patients in Tanzania, India and the UK respectively. The cost of giving TXA to 1,000 patients was $17,483 in Tanzania, $19,550 in India and $30,830 in the UK. The incremental cost of giving TXA versus not giving TXA was $18,025 in Tanzania, $20,670 in India and $48,002 in the UK. The estimated incremental cost per LY gained of administering TXA is $48, $66 and $64 in Tanzania, India and the UK respectively.

Conclusion: Early administration of TXA to bleeding trauma patients is likely to be highly cost effective in low, middle and high income settings.

Trial registration: This paper uses data collected by the CRASH 2 trial: Controlled-Trials.com ISRCTN86750102, Clinicaltrials.govNCT00375258 and South African Clinical Trial Register DOH-27-0607-1919.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Hazard rate following trauma.
Figure 1. Hazard rate following trauma.
Figure 2. Cost-effectiveness acceptability curves showing the…
Figure 2. Cost-effectiveness acceptability curves showing the probability of TXA being cost effective in Tanzania, India and the UK.

References

    1. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T. Under review. The effect of tranexamic acid on death due to bleeding: Time to treatment is critical.
    1. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;Jul 3;376(9734):23–32.
    1. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005;76:314–319.
    1. Guerriero C, Cairns J, Jayaraman S, Roberts I, Perel P, et al. Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation. Cost Eff Resour Alloc. 2010;8:1.
    1. World Bank. 2010. GDP (current US$)
    1. World Bank. 2010. Health Indicators.
    1. World Bank. 2010. Economic Policy and External Debt.
    1. WHO. 2010. Life Tables for Member States.
    1. Cleves Mario, Gould William W, Gutierrez Roberto G, Marchenko Y., editors. 2008. An introduction to survival analysis using STATA 2nd Edition.
    1. Tien P, Chu, Brenneman F. Causes of death following multiple trauma. Current Orthopaedics. 2004;18:304–310.
    1. National Institute for Clinical Excellence (NICE) Updated guide to the methods of technology appraisal. 2008. pp. 29–49.
    1. Penn World TableUniversity of Pennsylvania, editor. Purchaser Power Paritites. 2010.
    1. OECD. 2008. Purchasing Power Parities (PPP)
    1. British National Formulary. 2009.
    1. Private Communication with Muhimbili National Hospital Tanzania. 2010.
    1. CIA. The World Factbook. 2010. Country Comparison to the World. Inflation Rate (Consumer Prices)
    1. Bahalla JS, Meher MA. 2010. Nursing a Foreign Dream Hindustan times.
    1. GMC Chandigarh Hospital India. 2010.
    1. Private Communication with Care Hospital India. 2010.
    1. Curtis L Canterbury PSSRU, University of Kent, editor. Unit costs of health and social care; 2009. pp. 35–178.
    1. Trials Co-ordinating Centre (LSHTM) CRASH 2 trial (Clinical Randomization of an Antifibrinolytic in Significant Hemorrage) and Woman trial (World Maternal Antifibrinolytic Trial). 2009. London.
    1. Dziekan G, Chisholm D, Johns B, Rovira J, Hutin YJ. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Bull World Health Organ. 2003;81:277–285.
    1. WHO-CHOICE. United Republic of Tanzania. 2005. Estimates of Unit Costs for Patient Services for United Republic of Tanzania.
    1. WHO-CHOICE. India. 2005. Estimates of Unit Costs for Patient Services for India.
    1. Bureau of National Statistics. United States Department of Labor. 2009. Historical Consumer Price Index U.S. city average.
    1. Department of Health. 2010. NHS reference costs 2008–2009.
    1. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, et al. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg. 1999;68:2252–2256; discussion 2256–2257.
    1. Rajkumar S, Maharaj M, Chandrahas R, Padhy RK, PV S. Tranexamic acid in controlling the postoperative bleeding in open heart patients. Indian Journal of Thoracic Cardiovascualr Surgery. 2005;2005:207–211.
    1. Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg. 2008;106:1087–1100.
    1. Briggs A, Claxton K, Sculpher M. 2008. Decision Modelling for Health Economic Evaluation Oxford Handbook in Economic Evaluation Press OU, editor.
    1. Gerdtham UG, Zethraeus N. Predicting survival in cost-effectiveness analyses based on clinical trials. Int J Technol Assess Health Care. 2003;19:507–512.
    1. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2001.
    1. World Bank. 2010. Country Classification.
    1. Norton Robyn, Hyder Adnan A, Bishai David, Peden Margie. Unintentional Injuries. Disease Control Priorities in Developing Countries (2nd Edition) New York: Oxford University Press; 2006. pp. 737–754.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する